Anixa Biosciences (ANIX) Competitors

Anixa Biosciences (NASDAQ:ANIX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Does the media prefer ANIX or OLMA?

In the previous week, Anixa Biosciences had 9 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 14 mentions for Anixa Biosciences and 5 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.50 beat Anixa Biosciences' score of 1.19 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	6 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals believe in ANIX or OLMA?

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 22.6% of Anixa Biosciences shares are owned by company insiders. Comparatively, 19.4% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has higher valuation and earnings, ANIX or OLMA?

Anixa Biosciences has higher revenue and earnings than Olema Pharmaceuticals. Anixa Biosciences is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	369.30	-$9.81M	-$0.39	-6.18
Olema Pharmaceuticals	N/A	N/A	-$96.65M	-$2.19	-2.58

Which has more risk and volatility, ANIX or OLMA?

Anixa Biosciences has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500.

Does the MarketBeat Community prefer ANIX or OLMA?

Olema Pharmaceuticals received 6 more outperform votes than Anixa Biosciences when rated by MarketBeat users. However, 71.43% of users gave Anixa Biosciences an outperform vote while only 67.39% of users gave Olema Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Anixa Biosciences	Outperform Votes 25 71.43%	Underperform Votes 10 28.57%
Olema Pharmaceuticals	Outperform Votes 31 67.39%	Underperform Votes 15 32.61%

Is ANIX or OLMA more profitable?

Olema Pharmaceuticals' return on equity of -53.56% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-54.79%	-50.37%
Olema Pharmaceuticals	N/A	-53.56%	-47.86%

Do analysts recommend ANIX or OLMA?

Anixa Biosciences presently has a consensus target price of $8.50, suggesting a potential upside of 252.70%. Olema Pharmaceuticals has a consensus target price of $27.00, suggesting a potential upside of 377.03%. Given Olema Pharmaceuticals' higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Olema Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Olema Pharmaceuticals beats Anixa Biosciences on 9 of the 17 factors compared between the two stocks.